BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Mysterious bright blue cosmic blasts triggered by black holes shredding stars, scientists say. 'It's definitely not just an exploding star.' - 2Find Your Ideal Tea: Six Particular Assortments
- 3Posts falsely claim Netanyahu video fabricated to cover up his death
- 4Malaysia To Revive Search for Missing Flight MH370
- 56 Tire Brands Reasonable for Seniors
- A single shot of HPV vaccine may be enough to fight cervical cancer, study finds
- I served on the expert committee that advised the government on new dietary guidelines – most of our recommendations were ignored
- JW Marriott Tokyo: an elegant retreat amid whirlwind of the city
- The 10 Most Famous Works of art Ever
- Taylor Momsen explains why she quit 'Gossip Girl': 'I really didn't want to be there'
- Pick Your Favored kind of salad
- Key Business Regulations to Consider While Arranging Your Independent venture
- 2024's Driving Clearing Robots: Master Suggestions and Surveys
- Florence's Uffizi Gallery moves treasures to safety after cyberattack
